Year Founded
2023
Ownership
Private
Employees
~50
Therapeutic Areas
Oncology
Stage
Preclinical
Modalities
Small molecule

Hyku Biosciences General Information

Developing precision covalent medicines targeting non-cysteine amino acids (histidines, tyrosines, lysines) using proprietary chemoproteomics platform

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

No pipeline data available

For full access to Hyku Biosciences's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Hyku Biosciences Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Hyku Biosciences's complete valuation and funding history, request access »

Hyku Biosciences Investors

RA Capital Management / RAVen
Investor Type: Venture Capital
Holding: Minority
Droia Ventures
Investor Type: Venture Capital
Holding: Minority
Novartis Venture Fund
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 6 investors. Get the full list »